[1. American Psychological Association. Anxiey. Available at: http://www.apa.org/topics/anxiety/.]Search in Google Scholar
[2. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013; 43(5): 897-910.10.1017/S003329171200147X22781489]Search in Google Scholar
[3. Remes O, Brayne C, van der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016; 6(7): e00497.10.1002/brb3.497495162627458547]Search in Google Scholar
[4. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2): 92-98.10.1002/wps.20050368325123737408]Search in Google Scholar
[5. Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015; 17(2): 191-206.10.31887/DCNS.2015.17.2/proybyrne]Search in Google Scholar
[6. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol. 2007; 26(6): 872-8.10.1007/s10067-006-0407-y16941197]Search in Google Scholar
[7. Baqutayan SM. The effect of anxiety on breast cancer patients. Indian J Psychol Med. 2012; 34(2): 119-23.10.4103/0253-7176.101774349877223162185]Search in Google Scholar
[8. Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. Psychiatr Clin North Am. 2010; 33(3): 557-577.10.1016/j.psc.2010.04.00220599133]Search in Google Scholar
[9. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice. 2012; 16: 77-84.10.3109/13651501.2012.66711422540422]Search in Google Scholar
[10. Schaffer A, McIntosh D, Goldstein BI, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012; 24(1): 6-22.]Search in Google Scholar
[11. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009; 9: 38.10.1186/1471-244X-9-38270237719531229]Search in Google Scholar
[12. Monheit B, Pietrzak D, Hocking S. Prescription drug abuse - A timely update. Aust Fam Physician. 2016; 45(12): 862-866.]Search in Google Scholar
[13. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013. Am J Public Health. 2016; 106(4): 686-8.10.2105/AJPH.2016.303061481601026890165]Search in Google Scholar
[14. Stein MB, Roy-Byrne PP, Craske MG, et al Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry. 2011; 72(7): 970-976.10.4088/JCP.09m05626blu311181421367351]Search in Google Scholar
[15. Woodward SC, Bereznicki BJ, Westbury JL, Bereznicki LR. The effect of knowledge and expectations on adherence to and persistence with antidepressants. Patient Prefer Adherence. 2016; 10: 761-8.10.2147/PPA.S99803486682927226710]Search in Google Scholar
[16. Rubio-Valera M, Serrano-Blanco A, Travé P, Peñarrubia-María MT, Ruiz M, Pujol MM. Community Pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol. BMC Public Health. 2009; 9: 284.10.1186/1471-2458-9-284273175019656386]Search in Google Scholar
[17. Wright WA, Gorman JM, Odorzynski M, Peterson MJ, Clayton C. Integrated Pharmacies at Community Mental Health Centers: Medication Adherence and Outcomes. J Manag Care Spec Pharm. 2016; 22(11): 1330-1336.10.18553/jmcp.2016.1600427783555]Search in Google Scholar
[18. Freccero C, Sundquist K, Sundquist J, Ji J. Primary adherence to antidepressant prescriptions in primary health care: a population-based study in Sweden. Scand J Prim Health Care. 2016; 34(1): 83-8.10.3109/02813432.2015.1132884491102826828942]Search in Google Scholar
[19. Klang SH, Ben-Amnon Y, Cohen Y, Barak Y. Community Pharmacists’ support improves antidepressant adherence in the community. Int Clin Psychopharmacol. 2015; 30(6): 316-9.10.1097/YIC.000000000000009026163876]Search in Google Scholar
[20. Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorders. PT. 2013; 38(1): 30-57.]Search in Google Scholar
[21. Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2001; 62(Suppl 11): 46-50.]Search in Google Scholar
[22. Ravindran LN., Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010; 71(7): 839-854.10.4088/JCP.10r06218blu20667290]Search in Google Scholar
[23. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008; 9(4): 248-312.10.1080/1562297080246580718949648]Search in Google Scholar
[24. Pešić S. Antidepresivi i stabilizatori raspoloženja. In: Janković S. Farmakologija i toksikologija. 3th ed. Kragujevac: Medicinski fakultet. 2011: 217-34.]Search in Google Scholar
[25. Misri S, Burgmann A, Kostaras D. Are SSRIs safe for pregnant and breastfeeding women? Can Fam Physician. 2000; 46: 626-8, 631-3.]Search in Google Scholar
[26. Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12(1): 44-56.10.2174/1570159X1201140117162802391534924533015]Search in Google Scholar
[27. Ryvlin P, Perucca E, Rheims S. Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat. 2008; 4(6): 1211-24.10.2147/NDT.S4716264665019337461]Search in Google Scholar
[28. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013; 9: 883-92.10.2147/NDT.S36453]Search in Google Scholar
[29. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalized anxiety disorder. World J Biol Psychiatry. 2012; 13(7): 510-516.10.3109/15622975.2011.624548]Search in Google Scholar
[30. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007; 3(2): 185-91.10.2147/nedt.2007.3.2.185]Search in Google Scholar
[31. Patorno E, Bateman BT, Huybrechts KF, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017; 88(21): 2020-2025.10.1212/WNL.0000000000003959]Search in Google Scholar
[32. de Mesmaeker S, Zdanowicz N, Reynaert C, Jacques D. Role of benzodiazepines in the treatment of anxiety disorders in 2014. Psychiatr Danub. 2014; 26 Suppl 1: 23-6.]Search in Google Scholar
[33. Susman J, Klee B. The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder. Prim Care Companion J Clin Psychiatry. 2005; 7(1): 5-11.10.4088/PCC.v07n0101]Search in Google Scholar
[34. Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry. 2005; 66 Suppl 2: 21-7.]Search in Google Scholar
[35. Benzodiazepines: Revisiting Clinical Issues in Treating Anxiety Disorders. Prim Care Companion J Clin Psychiatry. 2005; 7(1): 23-32.10.4088/PCC.v07n0104]Search in Google Scholar
[36. Anxieties.com. Benzodiazepines (BZs). Available at: https://www.anxieties.com/157/benzodiazepinesbzs#.XCioR1xKjIU. Last time visited: Last time visited: 30.10.2018.]Search in Google Scholar
[37. Jovic Z. Anksiolitici (sedativi-hipnotici). In: Janković S. Farmakologija i toksikologija. 3th ed. Kragujevac: Medicinski fakultet 2011:178-94.]Search in Google Scholar
[38. Hayes PE, Schulz SC. Beta-blockers in anxiety disorders. J Affect Disord. 1987; 13(2): 119-30.10.1016/0165-0327(87)90017-6]Search in Google Scholar
[39. Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol 2016; 30(2): 128-39.10.1177/0269881115612236472479426487439]Search in Google Scholar
[40. Anxieties.com. Beta blockers. Available at:https://www.anxieties.com/159/betablockers#.XCj_VFxKjIU.]Search in Google Scholar
[41. Zohar J, Westenberg HG. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000; 403: 39-49.10.1111/j.1600-0447.2000.tb10947.x11019934]Search in Google Scholar
[42. Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf. 2014; 13(2): 207-25.10.1517/14740338.2014.86958224383525]Search in Google Scholar
[43. Hamann J, Linde K, Schweiger HD, Kusmakow O, Förstl H. Over-the-counter-drugs for the treatment of mood and anxiety disorders-the views of German pharmacists. Pharmacopsychiatry. 2014; 47(3): 84-8.10.1055/s-0034-137181024652700]Search in Google Scholar
[44. Sarris J, Stough C, Bousman CA, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psycho-pharmacol. 2013; 33(5): 643-8.10.1097/JCP.0b013e318291be6723635869]Search in Google Scholar
[45. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J. 2010; 9: 42.10.1186/1475-2891-9-42295908120929532]Search in Google Scholar
[46. Nunes A, Sousa M. [Use of valerian in anxiety and sleep disorders: what is the best evidence?]. Acta Med Port 2011;24 Suppl 4:961-6.]Search in Google Scholar
[47. World Health Organization. Improving Access And Use Of Psychotropic Medicines. Available at: http://apps.who.int/iris/bitstream/handle/10665/42883/9241546417.pdf.]Search in Google Scholar
[48. Vilarim MM, Rocha Araujo DM, Nardi AE. Caffeine challenge test and panic disorder: a systematic literature review. Exp Rev Neurotherapeutics. 2011; 11(8): 1185-1195.10.1586/ern.11.8321797659]Search in Google Scholar
[49. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009; 24(7): 515-523.10.1002/hup.104819693792]Search in Google Scholar
[50. Roy-Byrne PP, Uhde TW, Post RM. Effects of one night’s sleep deprivation on mood and behavior in panic disorder. Patients with panic disorder compared with depressed patients and normal controls. Arch Gen Psychiatry. 1986; 43(9): 895-899.10.1001/archpsyc.1986.018000900850113753167]Search in Google Scholar
[51. Wright WA, Gorman JM, Odorzynski M, Peterson MJ, Clayton C. Integrated Pharmacies at Community Mental Health Centers: Medication Adherence and Outcomes. J Manag Care Spec Pharm. 2016; 22(11): 1330-1336.10.18553/jmcp.2016.1600427783555]Search in Google Scholar
[52. Murphy AL, Gardner DM, Jacobs LM. Patient care activities by community Pharmacists in a capitation funding model mental health and addictions program. BMC Psychiatry. 2018; 18(1): 192.10.1186/s12888-018-1746-3600092729898682]Search in Google Scholar
[53. Martin P, Tamblyn R, Ahmed S, et al. An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial. Trials. 2013; 14(1): 80.10.1186/1745-6215-14-80362109923514019]Search in Google Scholar
[54. Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014; 77(2): 295-301.10.1111/j.1365-2125.2012.04418.x401401522882333]Search in Google Scholar
[55. Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ. Buyer beware? Does the information provided with herbal products available over-the-counter enable safe use? BMC Med. 2011; 9: 94.10.1186/1741-7015-9-94]Search in Google Scholar
[56. Di Y M, Li C G, Xue C C et al. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des. 2008; 14: 1723-1742.10.2174/13816120878474679818673195]Search in Google Scholar
[57. Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol. 2015; 89(6): 851-65.10.1007/s00204-015-1471-325680499]Search in Google Scholar
[58. Milosavljevic MN, Stefanovic SM, Milosavljevic MN, Kocovic AG, Jankovic SM. Uloga farmaceuta u prevenciji i otkrivanju interakcija OTC preparata: tehnika nominalne grupe. Racionalna terapija. 2018; 10(1): 1-12.10.5937/racter10-14500]Search in Google Scholar